PPD Opens New Research Center in China - Drug Discovery and Development

PPD, Inc. announced it has opened a vaccine clinical research center in Taizhou, China, further strengthening its clinical research and development services in one of the country’s major regions for conducting vaccine studies. Through the center, PPD will provide clinical monitoring services to global and local biopharmaceutical companies seeking to develop vaccines in China.

Located at the Taizhou China Medical City, the center will help biopharmaceutical companies address unique requirements for conducting vaccine clinical trials in the country. Vaccine studies in China are conducted by the Chinese Center for Disease Control and Prevention instead of at Phase 1 clinics or by investigators at hospitals, and they require thousands of patients for enrollment, compared to hundreds for studies conducted in other countries. Yet, China has a short recruitment period for vaccine trials.

“The vaccines market is one of the fastest growing segments in the industry, and in China the clinical trial market is growing at about 20 percent each year,” said Simon Britton, PPD’s vice president of clinical development for Asia Pacific. “Our strong expertise in vaccine clinical research and large presence in China make us well positioned to help our clients ensure adherence to global standards while addressing unique requirements for monitoring vaccine studies.”

The China Medical City has become a national hub for international and domestic pharmaceutical, biomedical and biotechnology companies and is part of a long-term plan to advance Taizhou as a global leader in research and development and position it as one of the world’s premier biopharmaceutical facilities.

PPD opened its first office in China in 2003 and is now the largest contract research organization in the country with nearly 1,100 employees. Its acquisitions of Excel PharmaStudies, Inc., and BioDuro LLC, last year strengthened the company’s drug discovery and development services in the country and advanced its goal of becoming China’s number one services provider for the biopharmaceutical industry.

Date: April 26, 2010
Source: PPD, Inc.